| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
20060 |
| Drug |
Atezolizumab in combination with bevacizumab |
| Brand |
Tecentriq® |
| Indication |
For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. |
| Rapid review commissioned |
21/12/2020 |
| Rapid review completed |
08/02/2021 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
24/02/2021 |
| Pre-submission consultation with Applicant |
22/11/2021 |
| Full submission received from Applicant |
26/07/2022 |
| Preliminary review sent to Applicant |
24/11/2022 |
| NCPE assessment re-commenced |
22/12/2022 |
| Factual accuracy sent to applicant |
08/03/2023 |
| NCPE assessment re-commenced |
15/03/2023 |
